Case Study: Emerging CAR T-Cell Therapy Company Achieves Faster BLA Submission Timelines with Veeva Systems

Emerging Biotech Improves Submission Timelines with Continuous Publishing

Therapy Company, an emerging CAR T-cell biotech with therapies in the pipeline, needed to speed up complex regulatory submissions across multiple regions while improving transparency and coordination. Managing filings through fragmented systems made it difficult to keep pace, especially for its Biologics License Application (BLA), and the team wanted to maintain in-house control. Veeva Systems, through Veeva RIM and Veeva Submissions Publishing, was brought in to help.

Veeva Systems implemented a unified RIM environment with continuous publishing, enabling parallel authoring, validation, and submission preparation in a single trusted platform. The solution was deployed in just three months and helped Therapy Company reduce manual rework and bottlenecks, improve collaboration, and file its BLA ahead of schedule; the team also reported being able to submit FDA documents within one hour of receipt.